Neurol. praxi. 2023;24(4):281-285 | DOI: 10.36290/neu.2023.046

Cognitive impairment in chronic migraine

MUDr. Petra Migaµová
Centrum pro diagnostiku a léčbu bolestí hlavy
Neurologická klinika FN Ostrava a LF Univerzita Ostrava, Katedra neurověd, Ostrava

Migraine is the third most common neurological disease. It i also one of the most disabling disease in the world. They are around one million patients with migraine in the Czech Republic. At least 50 000 women and men suffer from chronic migraine. Migraine is not only pain, but is also accompanied by other symptoms that complicate the life of patients. Patients with chronic migraine often complain of memory problems and difficulty concentrating. Insufficient concentration and memory can be trained and improved in a targeted manner.

Keywords: episodic and chronic migraine, brain fog, cognitiv impairment, cognitiv treatment.

Received: April 4, 2023; Revised: April 4, 2023; Accepted: June 16, 2023; Prepublished online: June 16, 2023; Published: September 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Migaµová P. Cognitive impairment in chronic migraine. Neurol. praxi. 2023;24(4):281-285. doi: 10.36290/neu.2023.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baars MAE, van Boxtel MPJ, Jolles J. Migraine does not affect cognitive decline: results from the Maastricht aging study. Headache. 2010;50(2):176-84. doi: 10.1111/j.1526-4610.2009.01572.x. Epub 2009 Nov 17. Go to original source... Go to PubMed...
    2. Bashir RB, Lipton S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta­‑analysis. Neurology. 2013;81(14):1260-1268. Go to original source... Go to PubMed...
    3. Beck JS. Cognitive behavior therapy: Basics and beyond (2nd ed.). New York: Guilford Press. 2011.
    4. Gu L, Wang Y, Shu H. Association between migraine and cognitive impairment. The journal of headache and pain. 2022;23. https://doi.org/10.1186/s10194-022-01462-4. Go to original source... Go to PubMed...
    5. Islamoska S, Hansen AM, Wang UX, et al. Mid- to late­‑life migraine diagnoses and risk of dementia: a national register­‑based follow­‑up study. The journal of Headache and Pain. 2020;21. doi: 10.1186/s10194-020-01166-7. Go to original source... Go to PubMed...
    6. Jiang W, Liang GH, Li JA, et al. Migraine and the risk of dementia: a meta­‑analysis and systematic review, Aging Clinical and experimental Research. Springer Link. 2022. doi: 10.1007/s40520-021-02065-w. Go to original source... Go to PubMed...
    7. Jin C, Yuan K, Zhao L, et al. Structural and functional abnormalities in migraine patients without aura. NMR in Biomedicine. 2013;26(1):58-64. Go to original source... Go to PubMed...
    8. Kim J, Suh SI, Seol H, et al. Regional grey matter changes in patients with migraine: a voxel­‑based morphometry study. Cephalalgia. 2008;28(6):598-604. Go to original source... Go to PubMed...
    9. Kulią»ák, P. Neuropsychologie. Praha: Portál. 2011: s. 314.
    10. Lai TH, Chou KH, Fuh JL, et al. Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia. 2016;36(14):1324-1333. Go to original source... Go to PubMed...
    11. Martins de Araújo C, Guimaraes Barbosa I, Aguilar Lemos SM, et al. Cognitive impairment in migraine: A systematic review. Dement neuropsychol. 2012;6(2):74-79. doi: 10.1590/S1980-57642012DN06020002. Go to original source... Go to PubMed...
    12. Neľádal T. Monoklonální protilátky v léčbě migrény, webinář Neurologie pro praxi Monoklonální protilátky v léčbě migrény a neuroimunologické aspekty koronaviru 17. 6. 2020.
    13. Recober A. Pathopfysiology of Migraine, Continuum (Minneap Minn). Haedache. 2021;27(3):586-596, doi: 10.1212/CON.0000000000000983. Go to original source... Go to PubMed...
    14. Ripa P, Ornello R, Pistoia F, et al. Spreading depolarization may link migraine, stroke, and other cardiovascular disease. Headache: The Journal of Head and Face Pain. 2015;55(1):180-182. Go to original source... Go to PubMed...
    15. Russo M, De Rosa MA, Calisi D, et al. Pharmacological Treatment and Cognitive Impairment: Risks and Benefits Int J Mol Sci. 2022;23(19):11418. doi: 10.3390/ijms231911418. Go to original source... Go to PubMed...
    16. Seng E. Migraine, Brain Fog and Memory Loss: How They Affect You; American Migraine foundantion, https://americanmigrainefoundation.org/resource­‑library/migraine­‑brain­‑fog/.
    17. Sharif S, Saleem A, Koumadoraki E, et al. Headache - A Window to Dementia: An Unexpected Twist. Cureus. 2021;13(2):e13398. doi: 10.7759/cureus.13398. Go to original source... Go to PubMed...
    18. Steiner TJ, Stovner LJ, Vos T. GBD 2015: Migraine is the third cause of disability in under 50 s. J Headache Pain. 2016;17(1):104. Go to original source... Go to PubMed...
    19. Tana C, Tafuri E, Tana M, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? Journal of Headache and Pain. 2013;14. Go to original source... Go to PubMed...
    20. Vuralli D, Ayata C, Bolay H. Cognitive dysfunction and migraine. The journal of Headache and Pain. 2018;19. doi.org/10.1186/s10194-018-0933-4. Go to original source... Go to PubMed...
    21. Wilson BA. The theory and practice of neuropsychological rehabilitation: I, B.A. Wilson (Ed.), Neuropsychological rehabilitation: Theory and practice. Lisse: Swets & Zeitlinger. 2003:1-10. Go to original source...
    22. Xiaoying C. Cognitive Decline in Chronic Migraine with Nonsteroid Anti-inflammation Drug Overuse: a cross- Sectional study, Pain Rseacrh and Management. 2019;7307198. Available form: https://doi.org/10.1155/2019/7307198. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.